Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system

Journal of Neurochemistry

Volumn 100, Issue 5, 2007, Pages 1375-1386

  Hunter, Randy L ^a   Dragicevic, Natasa ^a   Seifert, Kristen ^a   Choi, Dong Young ^a   Liu, Mei ^a   Kim, Hyoung Chun ^b   Cass, Wayne A ^a   Sullivan, Patrick G ^a   Bing, Guoying ^a,c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b Kangwon National University   (South Korea)

^c UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

Celecoxib; Lipopolysaccharide; Parkinson's disease; Pioglitazone

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DOPAMINE; LIPOPOLYSACCHARIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOENERGY; CELL ACTIVATION; CELL DAMAGE; CELL FUNCTION; CELL LOSS; CELL SURVIVAL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; ENCEPHALITIS; HYPOTHESIS; INFLAMMATION; MALE; MICROGLIA; MITOCHONDRIAL DYSFUNCTION; NERVE DEGENERATION; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; CELL DEATH; CORPUS STRIATUM; CYCLOOXYGENASE 2 INHIBITORS; DOPAMINE; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; MICROGLIA; MITOCHONDRIA; NERVE DEGENERATION; NEURONS; PPAR GAMMA; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, INSULIN; SUBSTANTIA NIGRA; SULFONAMIDES; THIAZOLIDINEDIONES;

RATTUS;

EID: 33847005101     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2006.04327.x     Document Type: Article

References (55)

1. Arimoto T. and Bing G. (2003) Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration. Neurobiol. Dis. 12, 35-45.
2. Arimoto T., Choi D. Y., Lu X., Liu M., Nguyen X. V., Zheng N., Stewart C. A., Kim H. C. and Bing G. (2006) Interleukin-10 protects against inflammation-mediated degeneration of dopaminergic neurons in substantia nigra. Neurobiol. Aging Epub ahead of print.
3. Banati R. B., Gehrmann J., Schubert P. and Kreutzberg G. W. (1993) Cytotoxicity of microglia. Glia 7, 111-118.
4. Bennett D. A., Beckett L. A., Murray A. M., Shannon K. M., Goetz C. G., Pilgrim D. M. and Evans D. A. (1996) Prevalence of parkinsonian signs and associated mortality in a community population of older people. N. Engl. J. Med. 334, 71-76.
5. Berger J. R. and Glitza I. C. (2003) Von's Economo's Encephalitis, in Clinical Neurovirology (Nath A. B. Jr, ed.), pp. 523-542. Marcel Dekker, New York.
6. Bing G. L. X., Zheng N. A., Jin L., Qi Y. and Kim H.-C. (1998) Microglia mediated dopaminergic cell death in the substantia nigra: a new animal model for Parkinson's disease. Neurosci. Abstr. 24, 44.
7. Breidert T., Callebert J., Heneka M. T., Landreth G., Launay J. M. and Hirsch E. C. (2002) Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J. Neurochem. 82, 615-624.
8. Brown M. R., Sullivan P. G., Dorenbos K. A., Modafferi E. A., Geddes J. W. and Steward O. (2004) Nitrogen disruption of synaptoneurosomes: an alternative method to isolate brain mitochondria. J. Neurosci. Methods 137, 299-303.
9. Brown M. R., Sullivan P. G. and Geddes J. W. (2006) Synaptic mitochondria are more susceptible to Ca2+overload than nonsynaptic mitochondria. J. Biol. Chem. 281, 11 658-11 668.
10. Casals J., Elizan T. S. and Yahr M. D. (1998) Postencephalitic parkinsonism - a review. J. Neural Transm. 105, 645-676.
11. Cass W. A., Harned M. E., Peters L. E., Nath A. and Mariagos W. F. (2003) HIV-1 protein Tat potentiation of methamphetamine-induced decreases in evoked overflow of dopamine in the striatum of the rat. Brain Res. 984, 133-142.
12. Castano A., Herrera A. J., Cano J. and Machado A. (1998) Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J. Neurochem. 70, 1584-1592.
13. Chalmanov V. and Vurbanova M. (1987) [Diabetes mellitus in parkinsonism patients]. Vutr. Boles. 26, 68-73.
14. Chen H., Zhang S. M., Hernan M. A., Schwarzschild M. A., Willett W. C., Colditz G. A., Speizer F. E. and Ascherio A. (2003) Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch. Neurol. 60, 1059-1064.
15. Crouser E. D., Julian M. W., Blaho D. V. and Pfeiffer D. R. (2002) Endotoxin-induced mitochondrial damage correlates with impaired respiratory activity. Crit. Care Med. 30, 276-284.
16. Dehmer T., Heneka M. T., Sastre M., Dichgans J. and Schulz J. B. (2004) Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J. Neurochem. 88, 494-501.
17. Feng Z. H., Wang T. G., Li D. D., Fung P., Wilson B. C., Liu B., Ali S. F., Langenbach R. and Hong J. S. (2002) Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl1, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra. Neurosci. Lett. 329, 354-358.
18. Forno L. S. (1996) Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55, 259-272.
19. Gao H. M., Hong J. S., Zhang W. and Liu B. (2002) Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J. Neurosci. 22, 782-790.
20. Greenamyre J. T., MacKenzie G., Peng T. I. and Stephans S. E. (1999) Mitochondrial dysfunction in Parkinson's disease. Biochem. Soc. Symp. 66, 85-97.
21. Hagg T. and Varon S. (1993) Ciliary neurotrophic factor prevents degeneration of adult rat substantia nigra dopaminergic neurons in vivo. Proc. Natl Acad. Sci. USA 90, 6315-6319.
22. He Y., Appel S. and Le W. (2001) Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res. 909, 187-193.
23. Herrera A. J., Castano A., Venero J. L., Cano J. and Machado A. (2000) The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol. Dis. 7, 429-447.
24. Hirsch E. C., Faucheux B., Damier P., Mouatt-Prigent A. and Agid Y. (1997) Neuronal vulnerability in Parkinson's disease. J. Neural Transm. Suppl. 50, 79-88.
25. Hsieh P. F., Chia L. G., Ni D. R., Cheng L. J., Ho Y. P., Tzeng S. F., Chang M. H. and Hong J. S. (2002) Behavior, neurochemistry and histology after intranigral lipopolysaccharide injection. Neuroreport 13, 277-280.
26. Iravani M. M., Kashefi K., Mander P., Rose S. and Jenner P. (2002) Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience 110, 49-58.
27. Jenner P. (1998) Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov. Disord. 13(Suppl. 1), 24-34.
28. Kim W. G., Mohney R. P., Wilson B., Jeohn G. H., Liu B. and Hong J. S. (2000) Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J. Neurosci. 20, 6309-6316.
29. Kim S. S., Kong P. J., Kim B. S., Sheen D. H., Nam S. Y. and Chun W. (2004) Inhibitory action of minocycline on lipopolysaccharide-induced release of nitric oxide and prostaglandin E2 in BV2 microglial cells. Arch. Pharm. Res. 27, 314-318.
30. Kuwabara T. and Imajoh-Ohmi S. (2004) LPS-induced apoptosis is dependent upon mitochondrial dysfunction. Apoptosis 9, 467-474.
31. Lang A. E. and Lozano A. M. (1998) Parkinson's disease. First of two parts. N. Engl. J. Med. 339, 1044-1053.
32. Lawson L. J., Perry V. H., Dri P. and Gordon S. (1990) Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 39, 151-170.
33. Liu B., Jiang J. W., Wilson B. C., Du L., Yang S. N., Wang J. Y., Wu G. C., Cao X. D. and Hong J. S. (2000) Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide. J. Pharmacol. Exp. Ther. 295, 125-132.
34. Lu X., Bing G. and Hagg T. (2000) Naloxone prevents microglia-induced degeneration of dopaminergic substantia nigra neurons in adult rats. Neuroscience 97, 285-291.
35. McGeer P. L., Itagaki S., Boyes B. E. and McGeer E. G. (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38, 1285-1291.
36. Minghetti L. and Levi G. (1998) Microglia as effector cells in brain damage and repair: focus on prostanoids and nitric oxide. Prog. Neurobiol. 54, 99-125.
37. Moroo I., Yamada T., Makino H., Tooyama I., McGeer P. L., McGeer E. G. and Hirayama K. (1994) Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease. Acta Neuropathol. (Berl) 87, 343-348.
38. Niehaus I. (2004) Lipopolysaccharides induce inflammation-mediated neurodegeneration in the substantia nigra and cerebral cortex (a case report), in New Trends in Alzheimer and Parkinson Related Disorders (Hanin I. F. A. and Cacabelos R., eds.), pp. 36-39. Monduzzi Editore, Bologna.
39. Olanow C. W. and Tatton W. G. (1999) Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 22, 123-144.
40. Paxinos G. and Watson C. (1998) The Rat Brain in Stereotaxic Coordinates, 5th Edn, plates 10-43. Academic Press, Sydney.
41. Qiu W. Q. and Folstein M. F. (2006) Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol. Aging 27, 190-198.
42. Schiess M. (2003) Nonsteroidal anti-inflammatory drugs protect against Parkinson neurodegeneration: can an NSAID a day keep Parkinson's disease away? Arch. Neurol. 60, 1043-1044.
43. Smith U. (2001) Pioglitazone: mechanism of action. Int. J. Clin. Pract. Suppl. 121, 13-18.
44. Sullivan P. G., Geiger J. D., Mattson M. P. and Scheff S. W. (2000) Dietary supplement creatine protects against traumatic brain injury. Ann. Neurol. 48, 723-729.
45. Sullivan P. G., Dube C., Dorenbos K., Steward O. and Baram T. Z. (2003) Mitochondrial uncoupling protein-2 protects the immature brain from excitotoxic neuronal death. Ann. Neurol. 53, 711-717.
46. Takahashi M., Yamada T., Tooyama I., Moroo I., Kimura H., Yamamoto T. and Okada H. (1996) Insulin receptor mRNA in the substantia nigra in Parkinson's disease. Neurosci. Lett. 204, 201-204.
47. Teismann P. and Ferger B. (2001) Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 39, 167-174.
48. Teismann P., Tieu K., Choi D. K., Wu D. C., Naini A., Hunot S., Vila M., Jackson-Lewis V. and Przedborski S. (2003) Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl Acad. Sci. USA 100, 5473-5478.
49. Ueki K., Kondo T. and Kahn C. R. (2004) Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol. Cell. Biol. 24, 5434-5446.
50. Unger J.W., Livingston J. N. and Moss A. M. (1991) Insulin receptors in the central nervous system: localization, signaling mechanisms and functional aspects. Prog. Neurobiol. 36, 343-362.
51. Vijitruth R., Liu M., Choi D. Y., Nguyen X., Hunter R. L. and Bing G. (2006) Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease. J. Neuroinflammation 3, 1742-2094.
52. Vila M., Jackson-Lewis V., Guegan C., Wu D. C., Teismann P., Choi D. K., Tieu K. and Przedborski S. (2001) The role of glial cells in Parkinson's disease. Curr. Opin. Neurol. 14, 483-489.
53. Welty-Wolf K. E., Simonson S. G., Huang Y. C., Fracica P. J., Patterson J. W. and Piantadosi C. A. (1996) Ultrastructural changes in skeletal muscle mitochondria in gram-negative sepsis. Shock 5, 378-384.
54. Xie Z., Smith C. J. and Van Eldik L. J. (2004) Activated glia induce neuron death via MAP kinase signaling pathways involving JNK and p38. Glia 45, 170-179.
55. Zhang J., Stanton D. M., Nguyen X. V., Liu M., Zhang Z., Gash D. and Bing G. (2005) Intrapallidal lipopolysaccharide injection increases iron and ferritin levels in glia of the rat substantia nigra and induces locomotor deficits. Neuroscience 135, 829-838.